Lonza board boots CEO Borgas

Pressure from Asian low-cost chemical and drug ingredient suppliers, combined with high Swiss energy costs impacting manufacturing operations, have yielded poor financial performance at Lonza and the ouster of CEO Stefan Borgas. "Our decision to replace Borgas was made during the past 48 hours and is backed by the board and management," said board chairman and acting-CEO Rolf Soiron. Story

Suggested Articles

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.

Celltrion remains optimistic it will get U.S. approval for its two biosimilar drugs, Rituxan and Herceptin, by the end of the year.